Pharmacist Salary in San Francisco, CA 2026,
$177,410 Median | BLS + Market Data

San Francisco pharmacists earn a BLS median of $177,410/yr, or $85.29 an hour, for the San Francisco-Oakland-Fremont metro, with a published band of $135,580 to $229,220. That is 7.8% above the California statewide figure and 25.9% above the US median. The metro employs 3,670 pharmacists at 0.75 times the national concentration.

Somewhat — 7.8% above the California statewide median. The gap is narrower than for most professions in this metro because California pays pharmacists well throughout: the state's pharmacist scope of practice, its board requirements and its large integrated health systems apply statewide, so a pharmacist in Sacramento or San Diego is not far behind.

Yes, and it is one of the genuinely distinctive features of this market. The region's concentration of drug developers creates pharmacist roles in medical affairs, regulatory affairs, pharmacovigilance and clinical development — jobs that use the doctoral training and clinical knowledge without any dispensing function. They typically want residency or fellowship training and sit at the top of the published band. Most metros have essentially none of these positions.

Yes, and the gap has widened. Community and retail pharmacy occupies the lower quarter of this band, under pressure from chain consolidation, reduced hours and staffing constraints that have been a national story for several years. Health system practice sits at the median, specialty clinical roles above it, and industry roles at the top near $229,220. Setting is the dominant variable in this occupation, considerably more than years of experience.

A Doctor of Pharmacy degree from an accredited programme, completion of required intern hours, and passage of the national pharmacist licensure examination together with the California-specific jurisprudence examination, all administered through the State Board of Pharmacy. Licensure is statewide — San Francisco issues nothing separate. California's requirements are widely regarded as among the more demanding in the country, and licence portability into the state is correspondingly slower than out of it.

When the 75th and 90th percentiles sit close together, the market's well-paid roles are converging on a similar level rather than producing a long tail of exceptional earners. For pharmacy that is what one would expect: it is a licensed profession with structured scales, and even the highest-paid clinical and industry positions are salaried rather than entrepreneurial. The practical reading is that reaching the upper quarter is achievable through specialisation, but that going much beyond it is not really a feature of this occupation.

The routes into the upper part of this band — board-certified specialty practice, and industry medical affairs or regulatory work — almost all run through postgraduate residency or fellowship training. That is a one or two year commitment at reduced pay immediately after a doctoral degree, and it is the single most consequential career decision a pharmacist in this region makes. Community practice does not require it; nearly everything above the median effectively does.

This metro employs fewer pharmacists per worker than the country does, at 0.75 times the national concentration. Part of that is a young, insured population with lower per-capita dispensing volume than average, and part is the well-documented contraction in retail pharmacy staffing. What it means for individuals is that the growth in this market is not in the sector that employs the most pharmacists nationally — it is in clinical specialisation and in industry, both of which are gated by training rather than by openings.